Your browser doesn't support javascript.
loading
Sporadic superficial angiomyxomas demonstrate loss of PRKAR1A expression.
Hafeez, Farhaan; Krakowski, Andrew C; Lian, Christine G; Nazarian, Rosalynn M; Maleszewski, Joseph J.
Afiliação
  • Hafeez F; Department of Dermatology, St Luke's University Health Network, Temple University School of Medicine, Bethlehem, PA, USA.
  • Krakowski AC; Department of Dermatology, St Luke's University Health Network, Temple University School of Medicine, Bethlehem, PA, USA.
  • Lian CG; Division of Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Nazarian RM; Dermatopathology Unit, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Maleszewski JJ; Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.
Histopathology ; 80(6): 1001-1003, 2022 May.
Article em En | MEDLINE | ID: mdl-34532875
Superficial angiomyxomas are cutaneous mesenchymal tumours that typically present clinically as slow-growing, solitary, asymptomatic nodules that can occur at any age. Histopathologically, these dermal and subcutaneous tumours are characterized by abundant myxoid stroma, numerous thin-walled and often arbourising blood vessels, and spindled to stellate fibroblast-like cells. While usually sporadic, superficial angiomyxomas can occasionally be associated with Carney complex (CNC), an autosomal dominant disorder characterized by inactivating germline mutations in the 1-alpha regulatory subunit of protein kinase A (PRKAR1A) and various clinical manifestations, including cardiac myxomas, facial lentigines, epithelioid blue naevi, endocrinopathies and psammomatous melanotic schwannomas. In this study, we sought to characterize the presence or absence of PRKAR1A expression by immunohistochemistry (IHC) in sporadic superficial angiomyxomas based on our observations in an index case. In total, PRKAR1A immunohistochemical expression was determined in 15 sporadic superficial angiomyxoma cases retrieved from the surgical pathology archives. IHC demonstrated that the lesional cells in 12 cases (80%) were non-reactive to antibodies against PRKAR1A. This study provides evidence in support of a role for PRKAR1A in the development of clinically non-syndromic superficial angiomyxomas. Together with previous studies, this report demonstrates that PRKAR1A may play an important role in the development of a variety of myxomatous mesenchymal tumours.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Neoplasias Cardíacas / Mixoma Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Neoplasias Cardíacas / Mixoma Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article